I also believe the findings were rather small. It could simply be patient selection bias that produced the results. It's amazing how easy it is to make GBM data look good, but then it isn't. From below though, it certainly appears decent. Considering it's a device it should have no affect on the approval pathway for GBM drugs and biologicals.
--- ----- ----
The following summaries are based on notes taken during presentations at the 19th annual meeting of the Society for Neuro-Oncology, held in Miami Beach Florida, November 13-16 2014.
Wednesday November 12, 2014. Marriot Stanton Hotel
A couple days prior to the beginning of the SNO conference, a "satellite meeting" was held at the Marriot Stanton Hotel, South Beach, Miami. Highlights from these sessions included a talk by Eric Wong of Harvard Medical School and the Beth Israel Deaconess Medical Center. In a presentation entitled "Dexamethasone Exerts Profound Interference on NovoTTF-100A Efficacy for Recurrent Glioblastoma", Dr Wong presented retrospective data showing that patients treated with Tumor Treating Fields (NovoTTF, now called Optune) in a previous phase 3 trial had better response to this treament when they were taking less than 4.1 mg dexamethasone per day. The patients who had response to the electric fields (TTF) took 1-2 mg dexamethasone on average, while non-responders took higher doses (up to 6-7 mg). When the data was stratified by a dexamethasone intake of 4.1 mg per day, those taking under this amount had median overall survival of 11 months, while those taking more than this amount had median survival of only 4.8 months.
A talk by Kenneth Swanson of Harvard Medical School entitled "Disruption of Cell Division Within Anaphase by Tumor Treating Electric Fields (TTFields) Leads to Immunogenic Cell Death: Implications for Treating Gliobastoma" may shed some light on the reasons for the worse survival outcomes of patients treated with TTF who also took high doses of dexamethasone. In this talk, he described his work showing that NovoTTF disrupts cells as they enter anaphase, at the metaphase to anaphase transition, and made claims that a cytoskeletal protein called septin may be the true cellular target of NovoTTF. He also showed that NovoTTF-induced cell death leads to the exposure of calreticulin and other immunogenic molecules, and that part of the therapeutic effects of NovoTTF may be due to an activated immune response following immunogenic cell death. As dexamethasone in high doses has immunosuppressive effects, this could be the possible cause of the interference with NovoTTF of high dose dexamethasone. Swanson speculated that because NovoTTF partially acts through endoplasmic reticulum (ER) stress, other agents that also induce ER stress, such as celecoxib (Celebrex) may be synergistic with NovoTTF.
Recent KTRA News
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 09/24/2024 12:35:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/24/2024 12:30:08 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 09/20/2024 08:20:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2024 08:15:07 PM
- Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024 • PR Newswire (US) • 09/20/2024 01:25:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 09/18/2024 12:40:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2024 12:35:07 PM
- Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences • PR Newswire (US) • 09/18/2024 12:30:00 PM
- Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences • PR Newswire (US) • 09/18/2024 12:30:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 09/11/2024 12:40:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2024 12:35:09 PM
- Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study • PR Newswire (US) • 09/11/2024 12:30:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 09/09/2024 08:10:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 08:05:10 PM
- Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc. • PR Newswire (US) • 09/09/2024 12:30:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 09/03/2024 09:25:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/03/2024 09:20:24 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 08/19/2024 01:10:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 01:05:08 PM
- TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer • PR Newswire (US) • 08/19/2024 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/14/2024 04:15:13 AM
- Form S-4/A - Registration of securities, business combinations: [Amend] • Edgar (US Regulatory) • 08/12/2024 09:01:34 PM
- Form S-4/A - Registration of securities, business combinations: [Amend] • Edgar (US Regulatory) • 08/08/2024 09:30:36 PM
- Form S-4/A - Registration of securities, business combinations: [Amend] • Edgar (US Regulatory) • 07/19/2024 09:03:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2024 09:17:26 PM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM